• 1
    Jonsson R, Haga H-J, Gordon T. Sjögren's syndrome. In: KoopmanWJ, editor. Arthritis and allied conditions: a textbook of rheumatology. 14th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 173659.
  • 2
    Fox RI, Stern M, Michelson P. Update in Sjögren's syndrome. Curr Opin Rheumatol 2000; 12: 3918.
  • 3
    Xanthou G, Tapinos NI, Polihronis M, Nezis IP, Margaritis LH, Moutsopoulos HM. CD4 cytotoxic and dendritic cells in the immunopathologic lesion of Sjögren's syndrome. Clin Exp Immunol 1999; 118: 15463.
  • 4
    Stott DI, Hiepe F, Hummel M, Steinhauser G, Berek C. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease: the salivary glands of patients with Sjögren's syndrome. J Clin Invest 1998; 102: 93846.
  • 5
    Bodeutsch C, deWilde PC, Kater L, van den Hoogen FH, Hene RJ, van Houwelingen JC, et al. Monotypic plasma cells in labial salivary glands of patients with Sjögren's syndrome: prognosticator for systemic lymphoproliferative disease. J Clin Pathol 1993; 46: 1238.
  • 6
    Bahler DW, Swerdlow SH. Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sjögren's syndrome) begin as nonmalignant antigen-selected expansion. Blood 1998; 91: 186472.
  • 7
    Ferry JA, Harris NL. Atlas of lymphoid hyperplasia and lymphoma. 1st ed. Philadelphia: WB Saunders; 1997.
  • 8
    Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978; 89: 88892.
  • 9
    Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM, and the European Concerted Action on Sjögren's syndrome. Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum 1999; 42: 176572.
  • 10
    Bohnhorst J, Bjorgan MB, Thoen JE, Natvig JB, Thompson KM. Bm1-bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjögren's syndrome. J Immunol 2001; 167: 36108.
  • 11
    Bonhorst JO, Thoen JE, Natvig JB, Thompson KM. Significantly depressed percentage of CD27+ (memory) B cells among peripheral blood B cells in patients with primary Sjögren's syndrome. Scand J Immunol 2001; 54: 4217.
  • 12
    Bonhorst JO, Bjorgan MB, Thoen JE, Jonsson R, Natvig JB, Thompson KM. Abnormal B cell differentiation in primary Sjögren's syndrome results in a depressed percentage of circulating memory B cells and elevated levels of soluble CD27 that correlate with serum IgG concentration. Clin Immunol 2002; 103: 7988.
  • 13
    Hansen A, Odendahl M, Reiter K, Jacobi AM, Feist E, Scholze J, et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 2002; 46: 216071.
  • 14
    Brezinschek HP, Brezinschek RI, Lipsky PE. Analysis of the heavy chain repertoire of human peripheral B cells using single-cell polymerase chain reaction. J Immunol 1995; 155: 190202.
  • 15
    Brezinschek HP, Foster SJ, Brezinschek RI, Dorner T, Domiati-Saad R, Lipsky PE. Analysis of the human VH gene repertoire: differential effects of selection and somatic hypermutation on human peripheral CD5(+)/IgM+ and CD5(−)/IgM+ B cells. J Clin Invest 1997; 99: 2488501.
  • 16
    Hansen A, Jacobi A, Pruss A, Kaufmann O, Scholze J, Lipsky PE, et al. Comparison of immunoglobulin heavy chain rearrangements between peripheral and glandular B cells in a patient with primary Sjögren′s syndrome. Scand J Immunol 2003; 57: 4709.
  • 17
    Muto T, Muramatsu M, Taniwaki M, Kinoshita K, Honjo T. Isolation, tissue distribution, and chromosomal location of the human activation-induced cytidine deaminase (AID) gene. Genomics 2000; 68: 858.
  • 18
    Muramatsu M, Sankaranand VS, Anant S, Sugai M, Kinoshita K, Davidson NO, et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the mRNA-editing deaminase family in germinal center B cells. J Biol Chem 1999; 274: 184706.
  • 19
    Allman D, Jain A, Dent A, Maile RR, Selvaggi T, Kehry MR, et al. BCL-6 expression during B cell activation. Blood 1996; 87: 525768.
  • 20
    Cattoretti G, Chang CC, Cechova K, Zhang J, Ye BH, Falini B, et al. BCL-6 protein is expressed in germinal-center B cells. Blood 1995; 86: 4553.
  • 21
    Fox RI, Saito I. Criteria for diagnosis of Sjögren's syndrome. Rheum Dis Clin North Am 1994; 20: 391407.
  • 22
    Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 5548.
  • 23
    Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000; 165: 59709.
  • 24
    Yavuz S, Grammer AC, Yavuz AS, Nanki T, Lipsky PE. Comparative characteristics of μ chain and α chain transcripts expressed by individual tonsil plasma cells. Mol Immunol 2001; 38: 1934.
  • 25
    Ruzickova S, Pruss A, Odendahl M, Wolbart K, Burmester GR, Scholze J, et al. Chronic lymphocytic leukemia preceded by cold agglutinin disease: intraclonal immunoglobulin light chain diversity in VH4-34 expressing single leukemic B cells. Blood 2002; 100: 341922.
  • 26
    Kabat EA, Wu TT, Perry HM, Gottesmann KS, Foeller C. Sequences of proteins of immunological interest. 5th ed. Vol. 1. Bethesda (MD): National Institutes of Health; 1991.
  • 27
    Yamada M, Wassermann R, Reichard BA, Shane S, Caton AJ, Rovera G. Preferential utilization of specific immunoglobulin heavy chain diversity and joining segments in adult human peripheral blood B lymphocytes. J Exp Med 1991; 173: 395407.
  • 28
    Wang X, Stollar BD. Human immunoglobulin variable region gene analysis by single cell RT-PCR. J Immunol Methods 2000; 244: 21725.
  • 29
    Wang X, Stollar BD. Immunogobulin VH gene expression in human aging. Clin Immunol 1999; 93: 13242.
  • 30
    Yamoaka K, Miyasaka N, Sato K, Okuda M, Nishioka K. B cell hyperresponsiveness in Sjögren's syndrome. Autoimmunity 1989; 3: 2619.
  • 31
    Geha RS, Rosen FS. The genetic basis of immunoglobulin-class switching. N Engl J Med 1994; 330: 10089.
  • 32
    Fear D, McCloskey N, Felsenfeld G, Gould H. A detailed analysis of germline transcription in cytokine stimulated B cells including isolated single cells. Scand J Immunol 2001; 54 (Suppl 1): 537.
  • 33
    Perrier S, Serre AF, Dubost JJ, Beaujon G, Plazonnet MP, Albuisson E, et al. Increased serum levels of interleukin-10 in Sjögren's syndrome: correlation with increased IgG1. J Rheumatol 2000; 20: 15365.
  • 34
    Kronfeld U, Halse AK, Jonsson R, Bremell T, Tarkowski A, Carlsten H. Differential immunological aberrations in patients with primary and secondary Sjögren's syndrome. Scand J Immunol 1997; 45: 698705.
  • 35
    Halse A, Tengner P, Wahren-Herlenius M, Haga H, Jonsson R. Increased frequency of cells secreting interleukin-6 and interleukin-10 in peripheral blood of patients with primary Sjögren's syndrome. Scand J Immunol 1999; 49: 5338.
  • 36
    Hagiwara E, Pando J, Ishigatsubo Y, Klinman DM. Altered frequency of type 1 cytokine secreting cells in the peripheral blood of patients with primary Sjögren's syndrome. J Rheumatol 1998; 25: 8993.
  • 37
    Font J, Garcia-Carrasco M, Ramos-Casals M, Aldea AI, Cervera R, Ingelmo M, et al. The role of interleukin-10 promoter polymorphisms in the clinical expression of primary Sjögren's syndrome. Rheumatology (Oxford) 2002; 41: 102530.
  • 38
    Hulkkonen J, Pertovaara M, Antonen J, Lahdenpohja N, Pasternack A, Hurme M. Genetic association between interleukin-10 promoter region polymorphisms and primary Sjögren's syndrome. Arthritis Rheum 2001; 44: 1769.
  • 39
    Amft N, Bowman SJ. Chemokines and cell trafficking in Sjögren's syndrome. Scand J Immunol 2001; 54: 629.
  • 40
    Salomonsson S, Larsson P, Tengner P, Mellquist E, Hjelmstrom P, Wahren-Herlenius M. Expression of the B cell-attracting chemokine CXCL13 in the target organ and autoantibody production in ectopic lymphoid tissue in the chronic inflammatory disease Sjögren's syndrome. Scand J Immunol 2002; 55: 33642.
  • 41
    Hjelmstrom P. Lymphoid neogenesis: de novo formation of lymphoid tissue in chronic inflammation through homing chemokines. J Leukoc Biol 2001; 69: 3319.
  • 42
    Heimbächer C, Hansen A, Pruss A, Jacobi A, Reiter K, Lipsky PE, et al. Immunoglobulin Vκ light chain gene analysis in patients with Sjögren's syndrome. Arthritis Rheum 2001; 44: 62637.
  • 43
    Kaschner S, Hansen A, Jacobi A, Reiter K, Monson NL, Odendahl M, et al. Immunoglobulin Vλ light chain gene usage in patients with Sjögren's syndrome. Arthritis Rheum 2001; 44: 262032.
  • 44
    Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 1998; 188: 167989.
  • 45
    Boursier L, Dunn-Walters DK, Spencer J. Characteristics of IgVH genes used by human intestinal plasma cells from childhood. Immunol 1999; 97: 55864.
  • 46
    De Wildt RM, Tomlinson IM, van Venrooij WJ, Winter G, Hoet RM. Comparable heavy and light chain pairings in normal and systemic lupus erythematosus IgG+ B cells. Eur J Immunol 2000; 30: 25461.
  • 47
    Kocks C, Rajewsky K. Stable expression and somatic hypermutation of antibody V regions in B cell developmental pathways. Ann Rev Immunol 1989; 7: 53759.
  • 48
    Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik M, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416: 6037.